Hegde has more than 28 years of leadership experience at the intersection of drug discovery and clinical development and has seen multiple drugs from discovery through FDA approval.
Hegde has participated in the discovery of several New Chemical Entities, including now-marketed products Yuperli and Vibativ as well as clinical candidates currently in Phase 2 and Phase 3 development.
He joins Recursion after more than 15 years at Theravance Biopharma, a company that has been successful in building a diversified portfolio with the core purpose of creating medicines to help improve the lives of patients with serious illnesses.
Dr. Hegde first joined Theravance in 1999 where he rose from positions of increasing responsibility across pharmacology and biology into his most recent role as senior vice president of Research.
Prior to Theravance, Hegde spent nine years at Syntex Corp., later acquired by Roche. He obtained his Ph.D. in Pharmacology from the University of Houston and his B.Pharm/M.Pharm from the University of Mumbai.
As part of his anticipation of a broader industry trend, Hegde evaluated and studied the intersection of technology and biology in depth before choosing to move to Recursion.
Hegde joins several senior leaders at Recursion in migrating from the San Francisco Bay Area to Salt Lake City. Called Silicon Slopes, the Greater Salt Lake City area is increasingly being recognized as an international high-tech hub, able to attract incredible entrepreneurs and substantial venture funding.
Since its founding in 2013, Recursion has built one of the world's largest datasets mapping human cellular biology, using high-content imaging, and advanced two of its ML-discovered small molecules into clinical trials.
The company plans to advance additional programs into clinical development, on its own or with partners, over the next 18 months.
Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease.
Recursion applies causative perturbations to human cells to generate disease models and associated biological image data.
Recursion's rich, relatable database of more than two petabytes of biological images generated in-house on the company's robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial